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Abstract
Background Although constipation can be a chronic
and severe problem, it is largely treated empirically.
Evidence for the efﬁcacy of some of the older laxatives
from well-designed trials is limited. Patients often
report high levels of dissatisfaction with their treat-
ment, which is attributed to a lack of efﬁcacy or
unpleasant side-effects. Management guidelines and
recommendations are limited and are not sufﬁciently
current to include treatments that became available
more recently, such as prokinetic agents in Europe.
Purpose We present an overview of the pathophysiol-
ogy, diagnosis, current management and available
guidelines for the treatment of chronic constipation,
and include recent data on the efﬁcacy and potential
clinical use of the more newly available therapeutic
agents. Based on published algorithms and guidelines
on the management of chronic constipation, second-
ary pathologies and causes are ﬁrst excluded and then
diet, lifestyle, and, if available, behavioral measures
adopted. If these fail, bulk-forming, osmotic, and
stimulant laxatives can be used. If symptoms are not
satisfactorily resolved, a prokinetic agent such as
prucalopride can be prescribed. Biofeedback is rec-
ommended as a treatment for chronic constipation in
patients with disordered defecation. Surgery should
only be considered once all other treatment options
have been exhausted.
Keywords algorithm, constipation, dissatisfaction,
prokinetic, prucalopride.
INTRODUCTION
Constipation is very common and many or most
people are affected at some time in their life. However,
for up to a quarter of the population it is more than a
minor annoyance; for them, constipation can be
chronic, sometimes severe, and has a signiﬁcant, even
debilitating, effect on their quality of life.
1–3 Many
patients suffer in silence and try to self-medicate,
while for those who do seek medical help, treatments
can be unsatisfactory.
2,4 Nonetheless, in the authors’
experience, most patients can be helped with the right
treatment approach. There are few detailed guidelines
and recommendations available for the management of
chronic constipation, and these do not always include
more recently available treatments. Therefore, this
article provides a summary of the condition from a
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  2011 Blackwell Publishing Ltd 697European perspective, reviewing the pathophysiology,
diagnosis and current management of constipation,
including more recently available therapeutic agents.
It is estimated that constipation affects between 2%
and 27% of the population, depending on the deﬁnition
used,
5,6 with 12% of people worldwide reporting self-
deﬁned constipation.
7 However, the prevalence of
constipation can be underestimated, as at least 65%
of patients suffering from constipation do not seek
immediate medical advice, but use over-the-counter
(OTC) laxatives instead.
2,5
Constipation may be severe and chronic; in a survey
of over 10 000 individuals in the US, 14.7% met the
criteria for constipation and 45% of these respondents
reported having the condition for 5 years or more.
6
Some experience weeks without a bowel movement
and suffer from bloating, straining, defecation urge
with an inability to evacuate, and painful evacua-
tion.
2,3 Daily activities and ability to work can be
compromised, e.g., by discomfort, the need to be near a
toilet, and by the length of time it takes to defecate.
Measures of general health, social functioning, and
mental health are signiﬁcantly impaired compared
with healthy individuals and levels are comparable
with other conditions such as osteoarthritis, rheuma-
toid arthritis, chronic allergies and diabetes.
1
In a web-based survey of approximately 4600 US
respondents reporting one or more symptoms of
constipation, only one in four reported seeking
treatment from a doctor in the previous year.
2 Those
who do seek medical treatment are often not
effectively treated, and only between one-quarter to
two-thirds of patients with chronic constipation are
satisﬁed with their laxative treatment.
2,4 In a
European survey of 744 patients with chronic con-
stipation, almost half were using alternative treat-
ments (homeopathy, massage and acupuncture) and
one in three were not taking any medication.
4 Nearly
90% of respondents expressed interest in new
therapies.
PATHOPHYSIOLOGY
Constipation may be primary (idiopathic) or secondary
to other factors (Table 1).
8
Several sub-types of primary constipation are recog-
nized, however, patients can display symptoms con-
sistent with those from several sub-types. Constipation
may be slow-transit (prolonged delay in passage of stool
through the colon), or normal-transit. With slow and
normal-transit times, there may be functional obstruc-
tion in the form of dysfunction of pelvic ﬂoor and anal
sphincter muscles (anismus), leading to difﬁculty
in expelling stools from the anorectum, or there can
be no identiﬁable pathology with normal-transit
constipation (Fig. 1).
Table 1 Causes of secondary constipation
8
Cause Example
Organic Colorectal cancer, extra-intestinal mass, postinﬂammatory, ischemic or surgical stenosis
Endocrine or
metabolic
Diabetes mellitus, hypothyroidism, hypercalcemia, porphyria, chronic renal insufﬁciency, panhypopituitarism, pregnancy
Neurological Spinal cord injury, Parkinson’s disease, paraplegia, multiple sclerosis, autonomic neuropathy, Hirschsprung’s disease, chronic
intestinal pseudo-obstruction
Myogenic Myotonic dystrophy, dermatomyositis, scleroderma, amyloidosis, chronic intestinal pseudo-obstruction
Anorectal Anal ﬁssure, anal strictures, inﬂammatory bowel disease, proctitis
Drugs Opiates, antihypertensive agents, tricyclic antidepressants, iron preparations, anti-epileptic drugs, anti-Parkinsonian agents
(anticholinergic or dopaminergic)
Diet or lifestyle Low ﬁber diet, dehydration, inactive lifestyle
Normal-transit constipation   Most common subtype  Frequently overlaps with 
IBS-C
Slow-transit constipation 
Mostly characterized by 
reduced phasic colonic 
motor activity 
Common in women 
Pelvic floor dysfunction 
Poor coordination of 
pelvic floor and anal 
sphincter  
Considerable overlap with 
STC and NTC
Figure 1 Types of constipation.Primary (idiopathic) constipation can be conceptually categorized into three main types: normal-transit, slow-transit
and pelvic ﬂoor dysfunction. IBS-C, constipation predominant irritable bowel syndrome; STC, slow-transit constipation.
8
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Normal-transit constipation is probably the most
common form of constipation seen by general clini-
cians, although this has not formally been studied.
8,9
Stool traverses at a normal rate through the colon and
stool frequency may be normal, but patients feel
constipated.
10 This group of patients report difﬁculty
with evacuation, bloating, abdominal pain or discom-
fort and hard stools; however, reduced colonic transit
cannot be conﬁrmed.
11 Constipation based on a
patient’s report of frequency of bowel movements
may be underestimated without the use of a stool
diary.
10
On investigation, some patients in this group may
have increased rectal compliance, reduced rectal sen-
sation or both.
12 A signiﬁcant overlap exists between
this subgroup of constipation and the irritable bowel
syndrome (IBS) subgroup.
Slow-transit constipation
Approximately half of patients with symptoms refrac-
tory to supplementary ﬁber have a prolonged intestinal
transit time.
12 This group of patients has been found to
have signiﬁcant impairment of propulsive colonic
motor activity,
13 and signiﬁcantly diminished colonic
responses following a meal and on awakening in the
morning;
10 however, diurnal rhythm is usually pre-
served.
14 In some patients, slow transit may be the
result of an underlying defecation disorder, as colon
transit times can become normalized following treat-
ment (e.g., using biofeedback) for the underlying
problem.
15
The impaired motility in slow-transit constipation
may be due to a number of factors. Propagating
pressure waves in the colon, known as high amplitude
propagated contractions (HAPCs), are strong contrac-
tions that begin at variable points in the colon and
propagate towards the rectum. Several studies have
shown that HAPCs are signiﬁcantly decreased in
constipated patients.
14,16 A potential basis for these
impairments are abnormalities of the myenteric
plexus, characterized by a reduction in the number of
argyrophilic neurons and axons, and an increase in the
number of variably sized nuclei within ganglia.
17
Interstitial cells of Cajal may also be important since
their volume is signiﬁcantly reduced in patients with
slow-transit constipation.
18 Interstitial cells of Cajal
are required for generating the smooth muscle electri-
cal slow wave, thus determining its contractile activ-
ity. In the absence of an electrical slow wave,
contractile activity is reduced and irregular, resulting
in decreased intestinal transit.
18 Alternatively, the
excitatory extrinsic nervous input to the bowel may
be diminished, or extrinsic inhibitory activity to the
bowel may be enhanced.
Acetylcholine is a neurotransmitter at neuro-neuro-
nal and neuro-effector synaptic junctions within the
enteric nervous system (ENS), and release of acetyl-
choline from enteric postsynaptic cholinergic neurons
is the primary stimulant for spontaneous contractile
activity of colonic smooth muscle.
19 Compared with
healthy subjects, constipated patients display an
impaired colonic motor response to cholinergic
stimulation in the descending colon.
19 Serotonin
[5-hydroxytryptamine (5-HT)], released from entero-
chromafﬁn cells in the gastrointestinal (GI) tract,
stimulates neurons of the myenteric plexus to initiate
peristaltic and secretory reﬂexes. While it is clear that
5-HT signaling is dysfunctional in intestinal motility
disorders,
20 it is not yet apparent whether this is
underpinned by changes in the availability of 5-HT per
se, or whether 5-HT re-uptake mechanisms, receptor
density and/or function are diminished.
21
It has been suggested, but not anatomically proven,
that neuronal damage arising from neurodegeneration,
or from damage during pelvic surgery or childbirth,
reduces colonic motility and may underlie certain
cases of idiopathic slow-transit constipation.
22
Although the relationship between sex hormones
and chronic constipation is not clear, a decreased level
of ovarian and adrenal steroid hormones has been
reported in association with constipation.
23 Further-
more, one in vitro study proposed a mechanism for
slow-transit constipation where the over-expression of
progesterone receptors can down-regulate contractile
G-proteins and up-regulate inhibitory G-proteins in
colonic circular muscle cells.
24
Defecation disorders
A number of patients with chronic constipation
display a difﬁculty in expelling stools from the rectum.
This failure may be due to impaired rectal contraction,
paradoxical anal contraction, or inadequate anal relax-
ation.
25 Lack of coordination, or dyssynergia, of the
muscles involved in defecation is thought to be the
most likely cause,
26 but a high proportion of patients
may also show impaired rectal sensation.
25 Structural
abnormalities are less common but include rectal
prolapse and/or intussusceptions, rectocele (a hernia-
tion, usually of the anterior rectal wall towards the
vagina), and excessive perineal descent. In many
patients, pelvic ﬂoor dysfunction may contribute to
constipation with or without delayed transit, and as a
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be beneﬁcial in recent controlled trials.
27–29
Many constipated patients show reduced sensitivity
to slow rectal distension, suggesting that there may be
diminished sensory innervation to the rectum and
sigmoid colon. In addition to a reduced urge to
defecate, this may indicate an imbalance between
sympathetic and parasympathetic inﬂuences in some
constipated patients, associated with decreased propul-
sive motor activity and tone.
12
DIAGNOSIS OF CHRONIC CONSTIPATION
The duration and characteristics of the patient’s
symptoms must be assessed to distinguish chronic
from transient constipation. Transient constipation is
easily recognized by history, indicating constipation
started at a time of change in dietary habits, mobility
or lifestyle. Secondary constipation, as a consequence
of other factors (Table 1), should be identiﬁed and
treated accordingly.
Diagnostic resources
Rome III criteria The Rome III classiﬁcation system is
widely recognized as the only standardized symptom-
based diagnostic criteria for functional GI disorders
(FGIDs), including chronic constipation (Table 2).
30
Other deﬁnitions of chronic constipation are consis-
tent with the Rome III criteria but are less quantitative
and more subjective.
31,32 Although clinicians are aware
of the Rome criteria, these are used principally for
research purposes and are not widely applied in clinical
practice, with the possible exception of IBS.
33
However, the Rome Foundation diagnostic algorithm
project has recently published a new set of clinical
algorithms for FGIDs, including chronic constipation,
which make active use of the Rome criteria for
diagnostic and therapeutic management (discussed in
section entitled Review of currently available guide-
lines, recommendations and algorithms).
Bristol Stool Form Scale The Bristol Stool Form Scale
(BSFS)
34 is a useful visual aid that was designed to
assist in the evaluation of patients with constipation.
Using simple visual descriptors, it illustrates the
common stool forms and consistency on a 7-point
scale. It has been validated in a number of studies and
has been found to be easily understood by patients,
enabling them to recognize and thus classify the stool
type that most closely represents their own experience.
The form of the stool depends on the time that it
spends in the colon; therefore, the BSFS is a quick and
reliable indicator of transit time. It is particularly
useful in patients with self-reported constipation who
do not have infrequent bowel movements, to establish
that hard or lumpy stools are, indeed, present.
Diagnostic evaluation
Routine extensive diagnostic and physiological testing
is not recommended for chronic constipation.
32,35
However, in those not responding to initial treatment,
three main physiological tests can be used to assess
anorectal disorders (e.g., dyssynergic defecation): ano-
rectal manometry,
25,26,36 the balloon expulsion test
36
and colon transit studies.
36,37 If necessary, colonoscopy
can be used to detect the presence of lesions such as
rectal ulcers, inﬂammation or malignancy, and radio-
graphy of the abdomen can provide evidence for an
excessive amount of stool in the colon. Barium enema
plays a limited role today but can identify megacolon
and megarectum. Anorectal manometry and histology
of the nerve plexuses can be used to conﬁrm Hirsch-
sprung’s disease.
As discussed earlier, constipation may arise second-
ary to a variety of factors (Table 1).
8 Secondary causes
of constipation are recognized by careful history taking
and clinical examination, including a thorough rectal
examination (e.g., the 10-step approach described by
Talley).
38 Colonoscopy is recommended in case of
alarm symptoms and in those over 50 to screen for
colorectal cancer.
8,39 Alarm features suggestive of a
serious GI disorder requiring further investigation
include:
40
1 Weight loss.
2 Blood in the stool.
3 Anemia.
4 Sudden change in bowel habit after the age of 50.
5 Signiﬁcant abdominal pain.
6 Family history of colon cancer or inﬂammatory
bowel disease.
Table 2 Rome III criteria for chronic constipation
30
Criteria fulﬁlled for the last 3 months and symptom onset at
least 6 months prior to diagnosis
Presence of ‡2 of the following symptoms:
• Lumpy or hard stools in ‡25% of defecations
• Straining during ‡25% of defecations
• Sensation of incomplete evacuation for ‡25% of defecations
• Sensation of anorectal obstruction/blockage for ‡25% of defecations
• Manual maneuvers to facilitate ‡25% of defecations
(digital manipulations, pelvic ﬂoor support)
• <3 evacuations per week
Loose stools rarely present without the use of laxatives
Insufﬁcient criteria for irritable bowel syndrome
J. Tack et al. Neurogastroenterology and Motility
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recommended for chronic constipation. However, if
there is suspicion of metabolic causes, these can be
investigated with a complete blood cell count, bio-
chemical proﬁle, serum calcium, glucose levels and
thyroid function tests. If these give rise to suspicion,
serum protein electrophoresis, urine porphyrins, serum
parathyroid hormone and serum cortisol levels can be
considered, but this will only rarely be indicated.
10
TREATMENT OPTIONS
Current treatment options
Current laxatives aid defecation by decreasing stool
consistency (softening) and/or artiﬁcially or indirectly
stimulating colon motility, via one or more of a
number of mechanisms (Table 3).
41,42
Well-designed, placebo-controlled, blinded, clinical
trials of older laxatives are sparse. Although many
trials report improvements in the number of bowel
movements per week and some report improvements
of certain symptoms, many studies are small and lack
comprehensive clinically relevant treatment end-
points. Similarly, there is a lack of head-to-head
comparisons; hence, there is a lack of evidence to
determine whether one laxative class is superior to
another. It is also largely unknown if laxative treat-
ments address the impaired quality of life observed in
patients with chronic constipation, as most studies
have failed to assess quality of life measures. Indeed,
for some patients, laxatives can worsen certain symp-
toms, such as bloating and ﬂatulence.
43
Undigestible ﬁbers attract water, which leads to a
larger and softer fecal mass. Systematic reviews of
older studies indicate that ﬁber increases the number
of bowel movements, but the quality of these studies is
inconsistent and the treatment duration was usually
limited to 4 weeks or less.
42 It has been shown that
patients with slow transit and/or impaired defecation
are unlikely to respond to ﬁber.
44
Most comparative data suggest that lactulose and
polyethylene glycol (PEG) have similar efﬁcacy, but
with lower incidence of vomiting and ﬂatulence asso-
ciated with the latter.
45,46 PEG provides well-tolerated
and effective relief in constipated patients.
46,47 In a
6-month placebo-controlled study, 304 patients with
chronic constipation received either 17 g PEG or
placebo. Fifty-two percent of PEG-treated patients
compared with 11% of placebo-treated patients
(P < 0.001) were successfully relieved from constipa-
tion (according to modiﬁed Rome criteria) for more
than 50% of their treatment weeks. No treatment-
related safety differences were observed between the
PEG and placebo groups during the study, with the
exception of GI complaints (39.7% PEG-treated
patients vs 25% placebo-treated patients; P = 0.015).
This difference was observed due to abdominal disten-
sion, diarrhea, loose stools, ﬂatulence and nausea,
which are considered usual effects of laxative use.
48 In
addition, a retrospective study of institutional patients
with chronic constipation reported good long-term
Table 3 Drugs commonly used in the treatment of constipation
41,42
Laxative type Examples Proposed mode of action Potential limitations
Dietary ﬁber/bulking agents Wheat bran
Psyllium seed husk
Methylcellulose
Luminal water binding increases
stool bulk and reduces consistency
Flatulence and abdominal distension
Stool impaction (rarely)
Not recommended in frail, immobile,
or palliative care patients
Osmotic laxatives
Undigestible disaccharides
and sugar alcohols
Lactulose
Sorbitol
Luminal water binding by creating
an osmotic gradient
Bloating, ﬂatulence
Synthetic macromolecules PEG
Polycarbophil
Luminal water binding Bloating
Salinic laxatives Magnesium hydroxide
(e.g., milk of magnesia)
Magnesium citrate
Magnesium sulfate
Sodium phosfate
Luminal water binding
Increases ﬂuid excretion
Electrolyte imbalance (must be used
with caution in patients with
compromised renal or cardiac
function)
Stimulant laxatives
Diphenylmethane derivatives Bisacodyl,
sodium picosulfate
Act locally to stimulate colonic
motility, decrease water
absorption from large intestine
Abdominal discomfort and cramps
Anthraquinones Senna, aloe, cascara Act locally to stimulate colonic
motility, decrease water
absorption from large intestine
Abdominal discomfort and cramps
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49 and for up to 5 months
in a randomized prospective study in adult
50 and
pediatric constipated patients.
51
Stimulant laxatives act via the lumen to alter elec-
trolyte transport and increase intraluminal ﬂuid secre-
tion; when in contact with the mucosa they indirectly
stimulate sensory nerve endings, thereby stimulating
propulsion.
41,42 Based on older literature, stimulant
laxatives are more effective than placebo.
52 A recent 4-
week placebo-controlled trial with picosulfate 10 mg
daily showed that this laxative was superior to placebo
in increasing the number of (complete) spontaneous
bowel movements, and in improving symptoms of
straining and some aspects of quality of life. However,
nearly 50% of the patients down-titrated the dose.
53
Stimulant laxatives (especially bisacodyl) are tradition-
allyusedasrescuetherapyinrecenttherapeutictrialsin
chronic constipation, suggesting that they are consid-
ered to have superior efﬁcacy, although comparative
trials with other agents are lacking.
54,55 There is
evidence that stimulant laxatives may cause abdominal
pain.
56 Early concerns of a possible link between
chronic anthraquinone use, colonic inertia, and colon
cancer have not been substantiated.
37,57
In summary, a wide variety of laxatives are avail-
able, many of which are effective and well-tolerated in
most constipated patients. However, they are not
effective in all patients, and for some, the mode of
action or dosage schedule is unacceptable and leads to
patient dissatisfaction.
2 In Table 4, we have summa-
rized the available data on the use of dietary ﬁber,
laxatives, and treatment of chronic constipation.
40,55,58
Although the levels of evidence and grading of the
recommendations varies between the meta-analyzes,
in general:
1 Grade A recommendations are supported by good
evidence.
2 Grade B recommendations are supported by moderate
evidence.
3 Grade C recommendations are only supported by
poor evidence.
4 Grade 1 recommendations are supported by one or
more randomized clinical trials.
5 Grade 2 recommendations are supported by one or
more well-designed cohort or case-controlled studies.
6 Grade 3 recommendations are supported by expert
opinion based on clinical experience.
Recent controlled studies have established the efﬁ-
cacy of biofeedback in the management of chronic
constipation in those with defecatory disorders, but the
efﬁcacy seems less in those with slow-transit constipa-
tion.
27–29 This establishes biofeedback as the treatment
of choice for constipation with defecation disorders.
However, recognizing and diagnosing defecatory disor-
ders is beyond the scope of primary care practice, and is
usuallyonlydonebygastroenterologists.Moreover,this
therapy requires a patient who understands the concept
and aim of the biofeedback process, and a skilled and
motivated physiotherapist. Availability of experienced
therapists and reimbursement of biofeedback is prob-
lematic in most parts of Europe.
New pharmacological treatments for
constipation
Currently available treatments
Lubiprostone. Chloride channels play an important role
in ﬂuid transport and the maintenance of cell volume
and pH in a variety of tissue and cell types, and in
particular, in intestinal epithelial cells.
59 Nine separate
channels have been identiﬁed, of which the CIC-2
channel is of particular interest; when it is activated,
the secretion of intestinal ﬂuid is promoted.
60 The
Table 4 Evidence-based review of treatments for constipation
Recommendation
Agent/procedure Ramkumar &
Rao (2001)
58
ACG chronic constipation
task Force (2005)
55
American Society of Colon and
Rectal Surgeons (2007)
40
Dietary
ﬁber/bulking agent
1C B (psyllium) B (ﬁber/psyllium)
Osmotic laxatives 1B A (PEG and lactulose) A (PEG)
B (lactulose)
Diphenylmethanes
, anthraquinones 2B Insufﬁcient evidence (Grade B) C
Stool softeners – Insufﬁcient evidence (Grade B) C
Lubiprostone* – – A
Biofeedback therapy
 (selected cases) 1B Insufﬁcient evidence (Grade C) B
Surgery (severe colonic inertia) 2B – B
*Not available in Europe with the exception of Switzerland.
Recent controlled trial shows efﬁcacy of sodium picosulfate in patients with chronic constipation (Rome II).
53
Recent controlled trials indicate an established efﬁcacy for biofeedback in patients with disordered defection.
27–29
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consistency and may contribute to normal transit.
Lubiprostone activates chloride channels to increase
intestinal ﬂuid secretion.
61 However, its exact mech-
anism is unclear and may involve type-2 chloride
channels, cystic ﬁbrosis transmembrane conductance
regulator chloride channels and/or G-protein-coupled
prostaglandin receptors.
62 It has been shown to signif-
icantly increase bowel movement frequency [5.89
spontaneous bowel movement (SBM)/week vs 3.99,
P < 0.0001] and relieve other constipation-related
symptoms compared with placebo.
61,63 It was approved
by the FDA in 2006 for the treatment of chronic
idiopathic constipation in adults, and subsequently for
constipation-predominant IBS (IBS-C) in 2008, but,
apart from Switzerland,
64 it is not approved in Europe,
as the Marketing Authorization Application was with-
drawn in September 2009 as a result of a strategic
decision by Sucampo Pharma Europe, Ltd.
5-HT4 agonists. As has already been discussed, seroto-
nin is a critical component in the regulation of gut
motility, visceral sensitivity, and intestinal secretion,
acting via serotonin 5-HT4 receptors, which are ex-
pressed mainly by ENS interneurones. It is logical,
therefore, to target 5-HT4 receptors in developing
treatments for constipation. 5-HT4 receptor agonists
stimulate 5-HT4 receptors on ENS interneurones to
enhance the peristaltic reﬂex and have been shown to
be effective in the treatment of chronic constipation.
65
However, the poor selectivity of the early 5-HT4
receptor agonists, such as cisapride and tegaserod, has
affected their risk : beneﬁt proﬁle and has ultimately
restricted their clinical use. Cisapride, a member of the
substituted benzamide family, is a partial 5-HT4
receptor agonist that was widely used for the treatment
of gastro-esophageal reﬂux and dyspepsia before its
withdrawal from the market in July 2000. It was
associated with rare dose-dependent cardiac events,
including lengthening of the QT interval, syncope, and
ventricular arrhythmia in patients with predisposing
conditions.
66 This effect is now believed to be caused
by its interaction with the cardiac hERG potassium
channel.
67 Tegaserod, an aminoguanidine indole, is a
5-HT4/5-HT1 receptor partial agonist, a 5-HT2 receptor
antagonist, and has been shown to inhibit dopamine
and noradrenaline transporters.
68 It was previously
approved in the USA (but not in Europe, apart from
Switzerland), but was withdrawn in March 2009 be-
cause of a possible increased risk of cardiovascular
adverse events (AEs) and is now only available for
emergency use. Although the mechanisms underlying
these adverse effects are not clear, they are unlikely to
be related to 5-HT4 effects.
69,70 More recently, a num-
ber of new 5-HT4 receptor agonists, with better selec-
tivity proﬁles, have been developed.
Prucalopride. Prucalopride is highly selective for the 5-
HT4 receptor, unlike cisapride, displaying at least 150-
fold selectivity for its therapeutic target receptor.
68,71
Early studies demonstrated that it decreased colonic
transit time in normal and constipated subjects.
72,73
ThreelargerandomizedPhaseIIIcontrolledtrialswitha
total of 1977 patients (1750 female and 227 male) with
severe chronic constipation (deﬁned as £2 SCBM/week
foraminimumof6 monthswitheitherveryhardorhard
stools, sensation of incomplete evacuation or straining
duringdefecationforatleast25%ofthetime)conﬁrmed
that,averagedover12 weeks,bowelfunction(measured
as an increase of ‡1 SBM/week) was signiﬁcantly im-
proved in up to 69% of patients receiving the recom-
mendeddoseof2 mgprucalopride,withamediantimeof
2.5 h to ﬁrst SBM.
74–76 Transit studies showed that
prucalopride was found to accelerate gastric emptying,
small bowel transit,overall colontransit, andascending
colonic emptying in patients with functional constipa-
tion.
73 Phase III trials have also conﬁrmed that, in addi-
tion to improving bowel function, prucalopride
signiﬁcantly improves patient treatment satisfaction
and quality of life, and alleviates a broad spectrum of
constipation-related symptoms, including bloating,
abdominal discomfort, and defecation urge with inabil-
ity to evacuate.
74–77 The most common adverse reac-
tions (headache, nausea, diarrhea and abdominal pain)
were mild and usually disappeared after the ﬁrst day of
treatment.
78 Safety data from two randomized Phase I
cross-over trials showed no clinically signiﬁcant results
from 24-h Holter monitoring. No difference was ob-
served in the mean QT values corrected according to
Fridericia’s method (QTcF) when comparing prucalo-
pridewithplacebo,andnoQTcFvaluesexceeded500 ms
or increased >60 ms during the treatment periods.
79
These data indicate that there was no increased risk of
drug-induced QT prolongation in this study.
79 A ran-
domizedPhaseIIdose-escalatingsafetystudyconducted
in 89 elderly patients aged ‡65 years old with constipa-
tion (87.7% of whom had a history of cardiovascular
disease),alsoshowednoclinicallyrelevantdifferencesin
QT or QTcF time intervals between prucalopride and
placebo, suggesting there is no speciﬁc cardiovascular
safetyconcernintheelderly.
80Resultsfromalong-term
(24 months) open-label extension study show that
treatmentsatisfactionismaintainedwithprolongeduse;
no safety signals were recorded in this study.
81 Prucalo-
pridehasalsobeenshowntobeeffectiveintheelderly
82
and patients with opioid-induced constipation.
83
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for the treatment of chronic constipation in women in
whom laxatives fail to provide adequate relief, and now
represents a new therapeutic option in the manage-
ment of this condition. The therapeutic potential in
hypomotile disorders of both the upper and lower GI
tract, and the different pharmacological mode of
action, might be the reason why the regulatory
authorities have classiﬁed prucalopride in a separate
class to laxatives (WHO ATC classiﬁcation A03AE,
drugs for functional bowel disorders – acting on
serotonin receptors).
Experimental treatments
Opioid antagonists. Three mu-opioid antagonists (nal-
oxone, methylnaltrexone and alvimopan) are currently
under evaluation for the treatment of opiate-induced
constipation
84,85 and postoperative ileus.
86 Although
endogenous opioids may play a role in modulating GI
function,
87 early reports suggested that opioid antago-
nists are not effective in idiopathic constipation.
88
Linaclotide. Linaclotide is an agonist of guanylate cy-
clase-C receptors, which stimulates intestinal ﬂuid
secretion and transit. In early studies, it has been found
to increase bowel movement frequency and loosen
stool consistency.
89 A recently published dose range-
ﬁnding study and results from two Phase III trials in
1272 patients with chronic constipation, show that
linaclotide signiﬁcantly improved bowel function
(measured as ‡3 complete SBMs (SCBM) per week,
with an increase of ‡1 from baseline for ‡9 of 12 weeks)
in up to approximately 20% of patients.
90 The median
time to ﬁrst SBM was 21.9 h (150 lg).
91 Furthermore,
abdominal symptoms, global measures of constipation
Patient with chronic
constipation (infrequent or
hard stools or difficult to
pass stools)
History and physical
examination
Alarm features?
Technical examinations
as indicated
Constipating
drugs?
Stop drugs if possible
Adequate relief?
Drug-induced 
constipation
Abnormality
identified?
Organic disease with
constipation, treat
accordingly
Chronic functional
constipation
(Rome III criteria)
Education; lifestyle and
dietary measures
Initial or subsequent
addition of laxatives
Adequate relief?
Adequate relief?
Add/switch laxative
Long-term
management
Long-term
management
Adequate relief?
Refractory constipation
Long-term
management
Stop laxative and
commence with
enterokinetic drug
(prucalopride†)
Refer for additional
testing following Rome
guidelines for
refractory constipation
and difficult defecation
No
No No
No
Yes
Yes Yes
Yes
No Yes
Yes
No
No
Yes
No
Figure 2 Enterokinetic treatment algorithm. Once idiopathic chronic constipation has been identiﬁed (Rome III); and education, lifestyle and dietary
measures; and treatment with laxatives (response evaluable after 2–4 weeks) have failed to provide adequate relief, an enterokinetic agent can be
commenced (response to prucalopride evaluable after 4–12 weeks). If constipation symptoms are still refractory to pharmacological treatment,
patients should be referred for physiological testing as outlined in the published Rome algorithm for refractive constipation and difﬁcult defecation.
2 or 1 mg day
)1 if the patient is >65 years.
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  2011 Blackwell Publishing Ltd 704and quality of life were also signiﬁcantly improved
91,92
and there was no evidence of rebound constipation
upon treatment cessation.
93 The most common AEs
were GI-related, of which diarrhea had the highest
incidence.
91 Linaclotide is currently not licensed for
use in the EU.
Other 5-HT4 agonists. Other enterokinetic agents in
development include the 5-HT4 receptor agonists
TD-5108 (Phase II),
94 and ATI-7505 (Phase II).
95 A num-
ber of other prokinetic 5-HT4 receptor agonists have
been developed for GI disorders, which are of consider-
able therapeutic interest but are in the early stages of
development.
REVIEW OF CURRENTLY AVAILABLE
GUIDELINES, RECOMMENDATIONS AND
ALGORITHMS
Anumberofgroupshaveprovidedrecommendationsfor
the diagnosis and treatment of constipation;
32,35,40,96,97
however, no standardized treatment guidelines have
Refractory constipation:
no improvement with
high-fiber diet, laxatives
and prucalopride
Physiological testing:
anorectal manometry,
rectal balloon expulsion,
and colonic transit
Are anorectal
manometry and
balloon expulsion
both normal?
Slow transit
constipation
Is colonic
transit slow?
Functional
constipation
with
normal transit
Functional
defecation
disorder
Assess barium or
MR defecography
Are both tests
abnormal?
Is colonic
transit slow?
Does slow transit
normalize after correcting
defecation disorder
Does defecography
reveal disordered
defecation?
Functional defecation
disorder with
normal transit
Functional defecation
disorder with
slow transit
Yes
Yes
Yes
Yes
No
No
No Yes
Yes
1
2
3
4
56
No
No
No
7
8
9
10
11
12 13
14
Figure 3 Refractory constipation and difﬁcult defecation. (1) Patients who fulﬁll the criteria for functional constipation and those who have
not improved with an increase in dietary ﬁber and the use of simple laxatives, and with no alarm features, often warrant further physiological
assessment. (2) The three key physiological investigations are anorectal manometry, the balloon expulsion test, and a colonic transit study. (3, 4) If
both anorectal manometry and balloon expulsion are normal, the results of colonic transit testing enable characterization of the disorder as functional
constipation with slow (5) or normal transit (6). (7, 8) If both manometry and the rectal balloon expulsion test are abnormal, this is sufﬁcient to
diagnose a functional defecation disorder. (9) If only one of the anorectal manometry and balloon expulsion is abnormal, further testing using barium
or magnetic resonance defecography may be used to conﬁrm or exclude the diagnosis. (10) If defecography reveals features of disordered defecation,
a diagnosis of a functional defecation disorder can be made. (8) If defecography is not abnormal, then the patient does not fulﬁll criteria for the
diagnosis of a functional defecation disorder; further diagnosis then depends on the presence or absence of colonic transit delay (see above 4–6).
(11–13) Treatment of choice for disordered defecation is biofeedback. If there is no adequate response to therapy, further investigation may be
considered at this point. The presence of a functional defecation disorder does not exclude the diagnosis of slow colonic transit. Thus, depending on
the results of the colonic transit study, the patient can be characterized as suffering from a functional defecation disorder with slow (12) or
normal colonic transit. (13, 14) Slow colonic transit may result from a defecation disorder. If it is felt appropriate to distinguish between the
two possibilities, the colonic transit evaluation may be repeated after correction of the defecation disorder. If transit normalizes, the presumption is
that the delay was secondary to the defecation disorder; if not, the delayed colonic transit is presumed to be a comorbid condition, which may
require therapy if there is no clinical improvement with the treatment of functional defecation disorder. This ﬁgure has been adapted by permission
from Macmillan Publishers Ltd: The American Journal of Gastroenterology,
36 copyright (2010).
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the evidence for a number of interventions (including
modiﬁcations to diet and lifestyle) is weak or contradic-
tory, all the guidelines recommend that these be tried
before pharmacological intervention. In general, where
treatment pathways are recommended, the sequence is:
1 Exclude other pathologies and secondary
causes.
35,40,55,96,97
2 Begin treatment with dietary and lifestyle adjust-
ments.
35,40,55,96,97
3 Move to osmotic laxatives, stool softeners and bulk-
forming agents – there is no consensus on the order
in which these should be tried.
35,96,97
4 Move to stimulant laxatives, suppositories and/or
enemas
96,97 – some guidelines recommend medical
supervision at this stage.
97
5 Surgery should be used as a last resort or to
treat identiﬁed disorders that require surgical
correction.
40,97
Although prokinetic agents feature in the two sets of
US guidelines (Grade A recommendation),
40,55 these
are now out of date. Tegaserod has now been limited to
emergency use in the US and has not received
licensing approval in the EU. Prucalopride has recently
received EU approval for the treatment of chronic
constipation in women in whom laxatives fail to
provide adequate relief; this is not mentioned in the
guidelines.
Once organic disorders and obstructions have been
excluded, a functional bowel disorder is the most likely
explanation for the constipation. Most patients with
chronic constipation report minimal abdominal bloat-
ing or discomfort associated with their other symp-
toms of chronic constipation; however, in some
patients, as symptoms often overlap, it may be difﬁcult
to distinguish chronic constipation and IBS-C.
55 The
American College of Gastroenterology (ACG) Chronic
Constipation Task Force deﬁned IBS-C as clinically
important abdominal discomfort associated with
symptoms of constipation.
61 National Institute for
Clinical Excellence (NICE) guidelines for IBS indicate
a positive diagnosis only if the person has abdominal
pain/discomfort that is either relieved by defecation, or
associated with altered bowel frequency or stool form,
and at least two of the following: altered stool passage;
abdominal bloating, distension, tension, or hardness,
symptoms made worse by eating and passage of
mucus.
98
As previously mentioned, guidelines and algorithms
for the management and treatment of chronic consti-
pation have not taken into account more recent
therapeutic developments. Although a new set of
Rome Foundation diagnostic algorithms covering the
diagnosis and management of FGIDs including chronic
constipation
35 and refractory constipation
36 have been
recently published, newer agents have not been
included. According to these guidelines, patients with
constipation that is refractory to a high-ﬁber diet and
traditional laxatives should be referred for physiologi-
cal testing, such as anorectal manometry, rectal
balloon expulsion, and colon transit. Now, with the
recent availability of prokinetic agents such as prucal-
opride, an additional therapeutic step can be added to
these existing guidelines. Once idiopathic chronic
constipation has been identiﬁed, and IBS and secondary
constipation have been excluded, empirical treatment
with osmotic and/or stimulant laxatives should be
employed. Following this, if patients still experience
continuous symptoms (e.g., bloating, abdominal dis-
comfort and incomplete bowel movements), a proki-
netic agent such as prucalopride could be considered
(Fig. 2). If constipation symptoms are refractory to
pharmacological treatment, patients should be referred
for physiological testing as outlined in the published
Rome algorithm for refractive constipation and difﬁ-
cult defecation (Fig. 3).
36 Patients should only be
referred for surgery following colon transit testing
without, and then with, laxatives.
CONCLUSIONS
Constipation is common and for some it can be
chronic, where symptoms can be severe and can
signiﬁcantly affect a patient’s quality of life.
Although many laxative treatments are available,
either OTC or by prescription, patients may often
need additional treatment to achieve optimal symp-
tom relief. As evidence for the effectiveness for many
of the older laxatives is limited and there are
relatively few guidelines on the management of this
condition, treatment is often empirically-based. If
diet, lifestyle measures, and traditional laxative ther-
apies fail to provide adequate relief, the use of a
motility agent offers a novel mechanism of action
with therapeutic beneﬁt. The 5-HT4 agonist prucal-
opride, approved in the EU, increases colonic motil-
ity and is a valuable clinical option for the patient
who is dissatisﬁed or incompletely treated by laxa-
tives.
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